Optimal glycemic control in type 2 diabetic patients: Does including insulin treatment mean a better outcome?

Diabetes Care

Volumn 23, Issue SUPPL. 2, 2000, Pages

  Vaaler, Stein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; BODY WEIGHT; CONFERENCE PAPER; DIABETES CONTROL; DOSE RESPONSE; DRUG EFFECT; EDUCATION; EXPERIENCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; VASCULAR DISEASE; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 0034079720     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Brown SA: Studies of educational intervention and outcomes in diabetic adults: a meta-analysis revisited. Patient Educ Couns 16:189-215, 1990
2. Brown SA, Winter M, Upchurch S, Ramirez G, Anding R: Promoting weight loss in type II diabetes. Diabetes Care 19:613-624, 1996
3. Olefsky J, Reaven GM, Farquhar JW: Effects of weight reduction on obesity: studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 53:64-76, 1974
4. Laitinen JH, Ahola IE, Sarkkinen ES, Winberg RL, Harmaakorpilivonen PA, Uusitupa MI: Impact of intensified dietary therapy on energy and nutrient intakes and fatty acid composition of serum lipids in patients with recently diagnosed non-insulin-dependent diabetes mellitus. J Am Diet Assoc 93:276-283, 1993
5. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 21:1288-1294, 1998
6. Perri MG, Sears SF, Clark JE: Strategies for improving maintenance of weight loss. Diabetes Care 16:200-209, 1993
7. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
8. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352:854-865, 1998
9. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N: Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 11:685-691, 1994
10. Josse RG: Acarbose for the treatment of type 2 diabetes: the results of a Canadian multi-centre trial. Diabetes Res Clin Pract 28 (Suppl. 1):167-172, 1995
11. Goldberg RB, Einhom D, Lucas CP, Rendell MS, Damsbo P, Huang W-C, Strange P, Brodows RG: A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 21:1897-1903, 1998
12. Birkeland K, Furuseth K, Melander A, Mowinckel P, Vaaler S: Long-term randomized placebo-controlled double blind therapeutic comparison of glipizide and glibenclamide: glycemic control and insulin secretion during 15 months. Diabetes Care 17:45-49, 1994
13. Birkeland K, Rishaug U, Hanssen KF, Vaaler S: NIDDM: a rapid progressive disease: results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia 39: 1629-1633, 1996
14. Abraiara C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock, JP, Emanucle NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Diabetes Care 18:1113-1123, 1995
15. Griffin S: Diabetes care in general practice: meta-analysis of randomised control trials. BMJ 317:390-395, 1998
16. Bulpitt CJ, Palmer AJ, Battersby C, Fletcher AE: Association of symptoms of type 2 diabetic patients with seventy of disease, obesity and blood pressure. Diabetes Care 21: 111-115, 1998
17. Van der Does FE, Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ: Symptoms and well-being in relation to glycemic control in type 2 diabetes. Diabetes Care 19:204-210, 1996
18. Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy I., Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J,Taskinen M-R: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
19. Ohkuho Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Schichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 28: 103-117, 1995
20. Thorsby P, Hanssen KF, Kilhovd B, Rishaug U, Vaaler S, Birkeland KIB: Progression of albuminuria relates to glycaemic control in subjects with NIDDM: a 5 year prospective study (Abstract). Eur J Endocrinol 136 (Suppl. 1):16, 1997
21. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
22. Andersson DK, Svärdsudd K: Long-term glycemic control relaies to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
23. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L: Randomised trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 26:57-65, 1995